Molecular Partners AG (MOLN) stock
MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 1/30
$2.67−0.19 (-6.82%)
Close on Nov 18, 2026Market cap $107.60MP/E –Yield –
Molecular Partners operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -CHF 58.12M. The highest annual figure on record is CHF 116.61M in fiscal 2022.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -CHF 58.12M | – |
| FY2024 | Dec 31, 2024 | -CHF 61.22M | – |
| FY2023 | Dec 31, 2023 | -CHF 61.11M | -152.4% |
| FY2022 | Dec 31, 2022 | CHF 116.61M | – |
| FY2021 | Dec 31, 2021 | -CHF 63.42M | – |
| FY2020 | Dec 31, 2020 | -CHF 58.33M | – |
| FY2019 | Dec 31, 2019 | -CHF 36.66M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -CHF 13.59M | – |
| Q2 FY2025 | Jun 30, 2025 | -CHF 17.32M | – |
| Q2 FY2024 | Jun 30, 2024 | -CHF 15.98M | – |
| Q2 FY2023 | Jun 30, 2023 | -CHF 15.88M | – |
| Q2 FY2022 | Jun 30, 2022 | -CHF 6.29M | – |
See a number that looks wrong?